Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 4/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25962384 | 0.80 | PRKCI (0.47) | PRKCIAXLJAK3NUDT1JAK1 | |
| SCHEMBL26220089 | 0.80 | PRKCI (0.61) | PRKCIAXLTBK1IKBKEJAK3 | |
| SCHEMBL24945674 | 0.79 | PRKCI (0.46) | PRKCIAXLJAK3NUDT1JAK1 | |
| SCHEMBL1565472 | 0.78 | PRKCI (0.53) | PRKCIAXLMAPK1JAK3NUDT1 | |
| SCHEMBL18926217 | 0.76 | PRKCI (0.44) | PRKCIAXLJAK3NUDT1JAK1 | |
| SCHEMBL22435946 | 0.76 | PTK2 (0.48) | PRKCIAXLJAK3JAK1JAK2 | |
| SCHEMBL23463555 | 0.76 | PRKCI (0.44) | PRKCIAXLJAK3NUDT1JAK1 | |
| SCHEMBL1134969 | 0.76 | PRKCI (0.44) | PRKCIAXLJAK3NUDT1JAK1 | |
| SCHEMBL27038129 | 0.76 | PRKCI (0.44) | PRKCIAXLMAPK1NUDT1EGFR | |
| SCHEMBL30698620 | 0.76 | PRKCI (0.44) | PRKCIAXLMAPK1NUDT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020081689-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |